There was no significant difference between patients treated with the experimental therapy of paclitaxel plus carboplatin and control treatments over a median follow-up period of 51 months. There was no significant difference in the occurrence of the secondary endpoint of progression-free survival.
There were differences in side-effect profiles:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.